These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38445848)

  • 61. Epidemiology and natural history of hepatitis C virus infection among children and young people.
    Modin L; Arshad A; Wilkes B; Benselin J; Lloyd C; Irving WL; Kelly DA
    J Hepatol; 2019 Mar; 70(3):371-378. PubMed ID: 30496763
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
    Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
    Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
    Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk factors of unfavorable prognosis of chronic hepatitis C.
    Shchanitcyna SE; Burnevich EZ; Nikulkina EN; Filatova AL; Мoiseev SV; Мukhin NA
    Ter Arkh; 2019 Mar; 91(2):59-66. PubMed ID: 31094173
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
    J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios.
    Harris RJ; Thomas B; Griffiths J; Costella A; Chapman R; Ramsay M; De Angelis D; Harris HE
    J Hepatol; 2014 Sep; 61(3):530-7. PubMed ID: 24824282
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term follow-up of chronic hepatitis C patients treated with interferon-alpha: risk of cirrhosis and hepatocellular carcinoma in a single center over 10 years.
    Lee HJ; Yeon JE; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Kim JH; Seo YS; Yim HJ; Byun KS
    Intervirology; 2015; 58(1):14-21. PubMed ID: 25592614
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A 2-year retrospective study of viral and host-associated risk factors in Pakistani hepatocellular carcinoma patients.
    Ul Abideen Z; Siddique S; Nasrullah I; Khan JS; Rehman S; Tong Y; Qamar R; Butt AM
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1103-1109. PubMed ID: 30829691
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
    Gane E; Stedman C; Brunton C; Radke S; Henderson C; Estes C; Razavi H
    N Z Med J; 2014 Dec; 127(1407):61-74. PubMed ID: 25530333
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.
    Le TK; Kalsekar A; Macaulay D; Yuan Y; Sorg RA; Behrer CR; Wei J; Wu EQ
    J Manag Care Spec Pharm; 2015 Apr; 21(4):308-18. PubMed ID: 25803764
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
    Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A model-based framework for chronic hepatitis C prevalence estimation.
    Hamadeh A; Feng Z; Krahn M; Wong WWL
    PLoS One; 2019; 14(11):e0225366. PubMed ID: 31751393
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
    Yoo HW; Park JY; Kim SG; Jung YK; Lee SH; Kim MY; Jun DW; Jang JY; Lee JW; Kwon OS
    Sci Rep; 2022 Jan; 12(1):193. PubMed ID: 34996920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.